Observatorio de I+D+i UPM

Go Back | Technology Solutions

DETECTALLERGEN. Improving the allergy diagnosis, improving your health.

More info

[DETECTALLERGEN]Commercial_sheet_UPM_EN(Innovatech) PDF
 
Briefing

Component resolved-diagnosis: low cost, high efficiency

Over 150 million people in Europe suffer from some type of allergy. Like other autoimmune diseases, allergies have to be treated as soon as possible to prevent associated degeneration damage. An effective diagnosis is necessary to reduce treatment cost and to improve the quality of patient. Over 30 million of diagnostic tests will be conducted the next year. So far, allergies have been diagnosed by using mixtures of allergens, making it difficult to determine which allergen is responsible for a particular allergy and find the right treatment. Componen resolved diagnosis means to use purified allergens as alternative test. This method provides an advantage over classic ways because it reduces the spending per patient (average savings of 6 euros) but also, it increases the efficiency of diagnosis (20-40%) what implies an improvement in the treatment and the quality of life of patients.

 
Technology Solution

Detectallergen: prueba cutánea

Detectallergen is specialized in the isolation of allergens to use in Component Resolved Diagnosis for allergies. Our products are manufactured under the strict GMP rules (GMP), with the highest standards of quality. That means that our products can be employed for diagnostic platforms and skin-prick test.

The use of purified allergens from known sources allows to diagnose allergy with high efficiency.

"A good diagnosis reduces the spending on allergy treatment up to 30% per person and year"

 
Market demands

  • 40% of the European population suffers from some type of allergies, and 30% of allergic children are diagnosed with asthma.
  • Annual expenditure of 3.6 billion € to European health systems in direct cost derived of allergies. Taking in account the indirect costs, the spending would be the double.
  • Only in work absences for medical reason, losses are estimated in 100 €/ patient and day. And the prevalence of allergies are increasing.
  • Allergies are degenerative diseases which require to be treated as soon as possible to reduce their associated degenerative symptoms. Therefore, the diagnosis is essential for patient-personalized treatments.
 
Market potential

  • Over a million of allergy tests will be conducted next year in Spain. At present, allergy diagnosis is mainly based on mixtures of allergens, being unable to determine the allergen responsible for a positive response. The same allergen may be present in various mixtures providing misleading results and the subsequent repetition of the test.
  • The cost of diagnosis is estimated at 10-14 €/patient (Spanish Ministry of Health, 2013). 20-40% out of the 60% positive results will need further confirmations in vitro diagnostic. This increases the cost (20-60 €).

"During 2015, a million people will be conducted an allergy test in Spain, with an average expenditure of 10-14 euros per person"

 

 
Competitive advantages

  • Component-resolved diagnosis requires to know exactly what allergen is responsible for the symptoms of an specific patient, for a more efficient treatment. Diagnosis by component requires allergy-specific purified allergens.
  • Since allergens can be found in more than one source, component-diagnosis results in the reduction of the number of samples to be tested, and in reading error in results (20-40% less) compared to classical diagnosis.
  • In Spain there are few companies specialized in component diagnosis of allergy and the offer of allergens is very reduced. Detectallergen lists over 40 allergens that cover 70% of the major allergies in Europe. It offers the most comprehensive list of allergens for different diagnosis techniques of allergies.
 
References

  • Products tested by more than 30 professionals of allergy diagnosis, which is reflected in a large number of scientific articles.
  • Likewise, we have supplied our purified allergens to ALK-Abello (company leader in allergy in Europe) since 2000. Currently, negotiations are established with other spanish laboratories.
 
Development stage

  • Concept
  • R&D
  • Lab Prototype
  • Industrial Prototype
  • Production
 
Contact

Contact DetectAllergen

Araceli Díaz Perales

Centre for Plant Biotechnology and Genomics (CBGP-UPM)

e: araceli.diaz@upm.es

w: http://www.cbgp.upm.es/allergenicity.php

UPM contact

Innovation, Commercialization and Entrepreneurship Area

Centre of Support for Technological Innovation - UPM

e: innovacion.tecnologica@upm.es

 
S2i 2019 Observatorio de investigación @ UPM con la colaboración del Consejo Social UPM
Cofinanciación del MINECO en el marco del Programa INNCIDE 2011 (OTR-2011-0236)
Cofinanciación del MINECO en el marco del Programa INNPACTO (IPT-020000-2010-22)